[email protected]: Australia's advantage
[email protected] will provide capability and innovative pathways for emerging and growing med-tech start-ups through specialist infrastructure and biomedical manufacturing capabilities, facilitating the pipeline of new start-ups.
How [email protected] will benefit the health of Australia's community and industry
- Developing national capabilities in the MTP sector
- Contributing to national innovation and capacity building of innovative business, manufacturing and industry
- Advancing research commercialisation and export opportunities
- Increasing ‘sovereign capability’ and manufacturing capability against pandemics
- Promoting engagement between the research sector, hospitals and industry
- Retaining MedTech start-up companies in Australia
- Creating a pipeline of start-ups transitioning from TRI to [email protected]
- Enhancing the reputation of Queensland and Australian innovation through research and commercialisation success - Eg. Gardasil HPV vaccine development as the foundation for TRI
- Providing practical cGMP training to early-career researchers and SMEs and building Australia's skilled workforce
- Creating jobs (direct and indirect) and spin-off benefits across multiple allied industries, including over 1400 construction jobs and 200 associated jobs every year for the first five years of its operation
- Increasing productivity through proximity to and collaboration with the established research and clinical expertise on the precint
- Attracting and retaining the best scientists, who can engage in leading research and development
- Increasing opportunities for Queenslanders and Australians to participate in clinical trials.
Register an Expression of Interest here: https://www.surveymonkey.com/r/7D8ZDJF.